Drugs / Pegbelfermin
Pegbelfermin
Trials 12
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2017-10-20 | Bristol-Myers Squibb | Results Bristol-Myers Squibb to Present New Data Advancing Research Across Serious Liver Diseases at The Liver Meeting® 2017 bms.com ↗
New analyses from a Phase 2 study of BMS-986036 (pegylated FGF21) in NASH further support non-invasive methods for assessing liver fibrosis |
| 2017-04-22 | Bristol-Myers Squibb | Results Bristol-Myers Squibb’s BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial bms.com ↗
The study achieved its primary endpoint of significant reduction in liver fat versus placebo. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-10-20 | Bristol-Myers Squibb | Bristol-Myers Squibb to Present New Data Advancing Research Across Serious Liver Diseases at The Liver Meeting® 2017 bms.com ↗ |
| 2017-04-22 | Bristol-Myers Squibb | Bristol-Myers Squibb’s BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial bms.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegbelfermin | “This study assessed pegbelfermin (BMS-986036), recombinant PEGylated human fibroblast growth factor 21 (FGF21), in patients with obesity and T2DM predisposed to fatty liver.” PMID 30520566 ↗ Dec 2018 |
| Known as | ARX-618 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297578 ↗ |
| Known as | BMS-986036 | “This study assessed pegbelfermin (BMS-986036), recombinant PEGylated human fibroblast growth factor 21 (FGF21), in patients with obesity and T2DM predisposed to fatty liver.” PMID 30520566 ↗ Dec 2018 |
| Known as | PEG-FGF21 | “A Phase 2B Randomized Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults With Nonalcoholic Steatohepatitis (NASH) and...” NCT03486899 ↗ |
| Known as | Pegbelfermina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297578 ↗ |
| Known as | Pegbelfermine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297578 ↗ |
| Modality | Protein / enzyme biologic | “recombinant PEGylated human fibroblast growth factor 21 (FGF21)” PMID 30520566 ↗ Dec 2018 |
| Route | Subcutaneous | “BMS-986036 1 mg subcutaneous injection once daily for 12 weeks” NCT02097277 ↗ |